导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.65% | 1576/4773 |
| 近一周 | -1.46% | 2190/5465 |
| 近一月 | -8.41% | 4929/5421 |
| 近一季 | -20.06% | 4923/5231 |
| 近半年 | 2.40% | 1051/4920 |
| 近一年 | 7.62% | 1449/4394 |
| 近两年 | 136.11% | 337/2954 |
| 近三年 | 86.54% | 209/2253 |
| 成立以来 | 36.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.04% 3498/4961 |
41.85% 737/5312 |
- - |
- - |
| 2025 | 60.97% 204/4813 |
-2.61% 2926/3635 |
5.01% 661/4076 |
58.13% 150/4524 |
-0.46% 2503/4813 |
| 2024 | 19.25% 538/3463 |
-2.62% 1392/2808 |
-6.07% 1844/3014 |
32.04% 103/3129 |
-1.26% 1638/3463 |
| 2023 | -23.85% 1963/2656 |
-1.54% 1874/2280 |
-8.67% 2010/2385 |
-9.96% 1917/2515 |
-5.96% 1574/2655 |
| 2022 | -29.50% 1603/2207 |
-21.74% 1649/1919 |
8.01% 405/2016 |
-19.03% 1747/2113 |
3.01% 787/2208 |
| 2021 | 12.11% 387/1822 |
-6.11% 978/1255 |
29.57% 49/1330 |
-7.79% 1082/1466 |
-0.02% 1183/1822 |
| 2020 | - - |
- - |
- - |
-1.42% 1066/1164 |
18.95% 85/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 西部利得创业板大盘ETF VS. 长安沪深300非周期A(740101) |